Table 2.
Cell growth inhibition of various cancer cell lines induced by analogs SM4-SM6.
| Cell line | SM4 | SM5 | SM6 | SM7 |
|---|---|---|---|---|
| Breast Cancer | EC50 (μM) | |||
| BTTR | 11.1±0.6 | 5.1±0.4 | 1.3±0.3 | 2.9±0.2 |
| BT-474 | NA | 10.8±2.1 | 2.7±0.3 | 7.0±0.3 |
| HCC1954 | NA | 17.5±0.6 | 3.0±0.4 | 19.8±1.5 |
| MCF-7 | NA | 16.8±0.7 | 13.4±1.3 | 24.4±1.6 |
| MDA-MB-231 | 32.3±1.3 | 15.1±0.8 | 7.2±0.5 | 10.9±0.2 |
| MDA-MB-361 | NA | 25.0±1.8 | 6.8±0.8 | 9.9±0.4 |
| T-47D | 28.2±3.3 | 19.3±0.9 | 6.2±0.3 | 9.0±0.2 |
| Liver Cancer | ||||
| HepG2 | 24.3±2.5 | 32.0±3.1 | 2.8±0.2 | 5.4±0.2 |
| Hep3B | 21.4±2.7 | 12.4±1.7 | 0.87±0.09 | 2.2±0.2 |
| Leukemia | ||||
| KOPN-8 | 8.2±0.5 | 5.9±0.5 | 3.6±1.1 | 11.1±0.9 |
| Molt-4 | 11.2±0.6 | 12.1±0.8 | 22.5 ±1.6 | NA |
| Nalm-6 | NA | 26.9±3.1 | 0.77±0.05 | 11.1±1.0 |
| Til-1 | 3.9±0.2 | 3.8±0.2 | 9.0±0.5 | 12.2±0.7 |
| Lymphoma | ||||
| CEM-TL | 6.2±0.1 | 6.5±0.7 | 3.6±0.9 | 3.5±0.3 |
| TF-1 | 12.2±0.5 | 8.8±0.5 | 3.2±0.1 | 5.2±0.2 |
| Melanoma | ||||
| M229 | 22.6±3.3 | 11.6±2.4 | 9.8±0.2 | 14.3±0.4 |
| Prostate Cancer | ||||
| DU145 | 45.4±3.8 | 12.2±1.6 | 4.9±0.4 | 9.3±0.5 |
| VCap | 12.9±0.6 | 8.9±0.2 | 12.2±0.5 | 18.1±0.8 |
| Colon Cancer | ||||
| T84 | NA | 11.1±1.7 | 9.3±0.6 | 10.6±1.0 |
| Head & Neck Cancer | ||||
| FaDu | 11.8±0.6 | 5.4±0.1 | 0.67±0.04 | 1.5±0.1 |